Alteration of von Willebrand Factor after Transcatheter Aortic Valve Replacement in the Absence of Paravalvular Regurgitation

Abstract

Moderate or severe paravalvular regurgitation after transcatheter aortic valve implantation (TAVI) is frequently associated with a loss of high-molecular-weight multimers of von Willebrand factor (VWF) and a reduced VWF collagen-binding capacity. It is unclear whether this phenomenon can also be observed in patients with mild paravalvular regurgitation, and whether there are differences between patients undergoing conventional aortic valve replacement (AVR) or TAVI. We analysed the multimeric structure of VWF and the ratio of VWF collagen-binding capacity to VWF antigen pre- and postoperatively in 12 patients scheduled for AVR and in 31 patients scheduled for TAVI. Echocardiographic examinations were performed pre-, intra- and postoperatively. Nine patients (75%) undergoing AVR and 18 patients (58%) undergoing TAVI showed pathological VWF functionality preoperatively (p = 0.48). Five to 7 days postoperatively, VWF functionality normalised in all patients with AVR, four of them with mild paravalvular regurgitation. VWF functionality was still altered in nine patients after TAVI (p = 0.044 between groups), five of them with and four without mild paravalvular regurgitation (p = 0.1).

Altered VWF functionality was observed in nearly one-third of patients after TAVI, but not after AVR. This phenomenon was not related to paravalvular regurgitation, but may indicate differences in the response of the haemostatic system to the prosthetic heart valve design or the valve replacement procedure.

Keywords

von Willebrand factor - aortic valve replacement - transcatheter aortic valve implantation - paravalvular regurgitation

• References

• 1 Pareti FI, Lattuada A, Bressi C. , et al. Proteolysis of von Willebrand factor and shear stress-induced platelet aggregation in patients with aortic valve stenosis. Circulation 2000; 102 (11) 1290-1295
• 2 Vincentelli A, Susen S, Le Tourneau T. , et al. Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med 2003; 349 (04) 343-349
• 3 Solomon C, Budde U, Schneppenheim S. , et al. Acquired type 2A von Willebrand syndrome caused by aortic valve disease corrects during valve surgery. Br J Anaesth 2011; 106 (04) 494-500
• 4 Bolliger D, Dell-Kuster S, Seeberger MD. , et al. Impact of loss of high-molecular-weight von Willebrand factor multimers on blood loss after aortic valve replacement. Br J Anaesth 2012; 108 (05) 754-762
• 5 Frank RD, Lanzmich R, Haager PK, Budde U. Severe aortic valve stenosis. Clin Appl Thromb Hemost 2017; 23 (03) 229-234
• 6 Yoshida K, Tobe S, Kawata M, Yamaguchi M. Acquired and reversible von Willebrand disease with high shear stress aortic valve stenosis. Ann Thorac Surg 2006; 81 (02) 490-494
• 7 Blackshear JL, McRee CW, Safford RE. , et al. Von Willebrand factor abnormalities and Heyde syndrome in dysfunctional heart valve prostheses. JAMA Cardiol 2016; 1 (02) 198-204
• 8 Van Belle E, Rauch A, Vincent F. , et al. Von Willebrand factor multimers during transcatheter aortic-valve replacement. N Engl J Med 2016; 375 (04) 335-344
• 9 Pibarot P, Hahn RT, Weissman NJ, Monaghan MJ. Assessment of paravalvular regurgitation following TAVR: a proposal of unifying grading scheme. JACC Cardiovasc Imaging 2015; 8 (03) 340-360
• 10 Federici AB, Rand JH, Bucciarelli P. , et al; Subcommittee on von Willebrand Factor. Acquired von Willebrand syndrome: data from an international registry. Thromb Haemost 2000; 84 (02) 345-349
• 11 Tiede A, Priesack J, Werwitzke S. , et al. Diagnostic workup of patients with acquired von Willebrand syndrome: a retrospective single-centre cohort study. J Thromb Haemost 2008; 6 (04) 569-576
• 12 Budde U, Schneppenheim R, Plendl H, Dent J, Ruggeri ZM, Zimmerman TS. Luminographic detection of von Willebrand factor multimers in agarose gels and on nitrocellulose membranes. Thromb Haemost 1990; 63 (02) 312-315
• 13 Baghai M, Heilmann C, Beyersdorf F. , et al. Platelet dysfunction and acquired von Willebrand syndrome in patients with left ventricular assist devices. Eur J Cardiothorac Surg 2015; 48 (03) 421-427
• 14 Vasa-Nicotera M, Sinning JM, Chin D. , et al. Impact of paravalvular leakage on outcome in patients after transcatheter aortic valve implantation. JACC Cardiovasc Interv 2012; 5 (08) 858-865
• 15 De Jong A, Eikenboom J. Developments in the diagnostic procedures for von Willebrand disease. J Thromb Haemost 2016; 14 (03) 449-460
• 16 Castaman G, Tosetto A, Cappelletti A. , et al. Validation of a rapid test (VWF-LIA) for the quantitative determination of von Willebrand factor antigen in type 1 von Willebrand disease diagnosis within the European multicenter study MCMDM-1VWD. Thromb Res 2010; 126 (03) 227-231
• 17 Steinlechner B, Zeidler P, Base E. , et al. Patients with severe aortic valve stenosis and impaired platelet function benefit from preoperative desmopressin infusion. Ann Thorac Surg 2011; 91 (05) 1420-1426
• 18 Mikkelsen MM, Fenger-Eriksen C, Johnsen SP, Christensen TD, Sørensen B. No excess surgical blood loss in patients with acquired type 2A von Willebrand disease. Scand Cardiovasc J 2011; 45 (02) 120-126
• 19 Spangenberg T, Budde U, Schewel D. , et al. Treatment of acquired von Willebrand syndrome in aortic stenosis with transcatheter aortic valve replacement. JACC Cardiovasc Interv 2015; 8 (05) 692-700
• 20 Adcock DM, Bethel M, Valcour A. Diagnosing von Willebrand disease: a large reference laboratory's perspective. Semin Thromb Hemost 2006; 32 (05) 472-479
• 21 Budde U, Pieconka A, Will K, Schneppenheim R. Laboratory testing for von Willebrand disease: contribution of multimer analysis to diagnosis and classification. Semin Thromb Hemost 2006; 32 (05) 514-521
• 22 Flood VH, Gill JC, Friedman KD. , et al; Zimmerman Program Investigators. Collagen binding provides a sensitive screen for variant von Willebrand disease. Clin Chem 2013; 59 (04) 684-691
• 23 Panzer S, Badr Eslam R, Schneller A. , et al. Loss of high-molecular-weight von Willebrand factor multimers mainly affects platelet aggregation in patients with aortic stenosis. Thromb Haemost 2010; 103 (02) 408-414
• 24 Mannucci PM, Parolari A, Canciani MT, Alemanni F, Camera M. Opposite changes of ADAMTS-13 and von Willebrand factor after cardiac surgery. J Thromb Haemost 2005; 3 (02) 397-399
• 25 Reinecke IR, Weber CF, Budde U, Seifried E, Miesbach WA. Prospective evaluation of ADAMTS-13 and von Willebrand factor multimers in cardiac surgery. Blood Coagul Fibrinolysis 2016; 27 (08) 886-891
• 26 Van Belle E, Rauch A, Vincentelli A. , et al. Von Willebrand factor as a biological sensor of blood flow to monitor percutaneous aortic valve interventions. Circ Res 2015; 116 (07) 1193-1201
• 27 Blackshear JL, Wysokinska EM, Safford RE. , et al. Shear stress-associated acquired von Willebrand syndrome in patients with mitral regurgitation. J Thromb Haemost 2014; 12 (12) 1966-1974
• 28 Hollestelle MJ, Loots CM, Squizzato A. , et al. Decreased active von Willebrand factor level owing to shear stress in aortic stenosis patients. J Thromb Haemost 2011; 9 (05) 953-958
• 29 Mueller T, Dieplinger B, Poelz W, Haltmayer M. Utility of the PFA-100 instrument and the novel multiplate analyzer for the assessment of aspirin and clopidogrel effects on platelet function in patients with cardiovascular disease. Clin Appl Thromb Hemost 2009; 15 (06) 652-659
• 30 Hayward CP, Harrison P, Cattaneo M, Ortel TL, Rao AK. ; Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost 2006; 4 (02) 312-319
• 31 Grau AJ, Reiners S, Lichy C, Buggle F, Ruf A. Platelet function under aspirin, clopidogrel, and both after ischemic stroke: a case-crossover study. Stroke 2003; 34 (04) 849-854
• 32 Nishimura RA, Otto CM, Bonow RO. , et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63 (22) e57-e185
• 33 Clavel MA, Webb JG, Pibarot P. , et al. Comparison of the hemodynamic performance of percutaneous and surgical bioprostheses for the treatment of severe aortic stenosis. J Am Coll Cardiol 2009; 53 (20) 1883-1891